Articles
-
1 week ago |
pharmacytimes.com | Hope Rugo |Alana Hippensteele
Trastuzumab deruxtecan (T-DXd, Enhertu; AstraZeneca and Daiichi Sankyo) has become a pivotal therapy in the treatment of HER2-positive cancers, yet its use is associated with the risk of interstitial lung disease (ILD), a potentially serious and sometimes fatal complication. As the oncology community works to balance efficacy with safety, the question of whether and how to safely rechallenge patients with T-DXd after ILD remains critical.
-
2 months ago |
mdpi.com | Hope Rugo |Aditya Bardia |Peter Schmid |Sara M. Tolaney
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Jan 15, 2025 |
targetedonc.com | Hope Rugo
2 Commerce Drive Cranbury, NJ 08512
-
Dec 31, 2024 |
targetedonc.com | Hope Rugo
2 Commerce Drive Cranbury, NJ 08512
-
Dec 11, 2024 |
targetedonc.com | Hope Rugo
2 Commerce Drive Cranbury, NJ 08512
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 10K
- Tweets
- 3K
- DMs Open
- No
Honored to be nominated for the ESMO nomination committee. Great candidates from around the world for the open positions - check them out on line! And vote! @myESMO #ESMO
📢It's #ESMO election time! I am delighted to be nominated for ESMO Director of Education 😊 ALL the nominees are fantastic representing the global @myESMO community 🌍 🙏for all the good wishes Rules this year for social media so that's it from me! Now please vote 🗳️ https://t.co/sbXenst0k0
Very nice review article impactful for clinical practice. Advancing breast cancer treatment in the era of molecular diagnostics - The Breast. @TheBreastOnline @curijoey @JavierCortesMD https://t.co/MunFnRJWXe
Wow. That is news I hadn’t seen yet. Lack of activity in wild type disease must be driving that change. Still too bad.
Arvinas lays off 33% of staff and discontinues two phase 3 trials of 1L vepdegestrant+CDK4/6i and 1L vepdegestrant+CDK4i (atirmociclib). Further development of the PROTAC will focus on the 2L setting. https://t.co/IQrJf59k0S
